• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives

Research Briefing on 3-(Dimethoxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (CAS: 1356110-05-8) in Chemical Biology and Pharmaceutical Applications

The compound 3-(Dimethoxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (CAS: 1356110-05-8) has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This boronic ester-functionalized pyridine derivative serves as a key intermediate in Suzuki-Miyaura cross-coupling reactions, enabling the synthesis of complex bioactive molecules. Recent studies highlight its role in the development of kinase inhibitors, proteolysis-targeting chimeras (PROTACs), and boron-containing therapeutics.

A 2023 study published in Journal of Medicinal Chemistry demonstrated the utility of this compound in constructing novel Bruton's tyrosine kinase (BTK) inhibitors. Researchers utilized its boronic ester moiety for late-stage diversification, achieving nanomolar potency against resistant BTK mutants. The dimethoxymethyl group was found to enhance metabolic stability compared to analogous compounds, addressing a common limitation in kinase drug development.

In the field of targeted protein degradation, a 2024 Nature Chemical Biology publication reported the successful incorporation of 1356110-05-8 into heterobifunctional PROTAC molecules. The compound's balanced hydrophobicity and steric properties enabled efficient ternary complex formation between target proteins and E3 ubiquitin ligases. Particularly noteworthy was its application in degrading previously "undruggable" transcription factors, opening new avenues in oncology drug discovery.

Structural-activity relationship (SAR) studies have revealed that the dioxaborolane ring system contributes to favorable pharmacokinetic properties by modulating the compound's membrane permeability and plasma protein binding characteristics. Nuclear magnetic resonance (NMR) analyses indicate that the dimethoxymethyl group adopts a conformation that minimizes steric clashes during protein-ligand interactions, as evidenced by X-ray crystallography data from several protein-ligand complexes.

Recent advances in synthetic methodology have improved the scalability of 1356110-05-8 production. A 2023 Organic Process Research & Development paper described a continuous flow process that achieves >90% yield with excellent purity (>99.5%), addressing previous challenges in large-scale preparation. This development is particularly significant given the growing demand for this intermediate in combinatorial chemistry and high-throughput screening platforms.

Emerging applications extend beyond small molecule therapeutics. Several research groups have successfully incorporated this building block into boron neutron capture therapy (BNCT) agents and positron emission tomography (PET) tracers. The compound's ability to serve as a ¹⁸F-radiolabeling precursor has enabled the development of novel imaging probes for neurodegenerative disease research.

While showing great promise, challenges remain in optimizing the in vivo stability of derivatives containing this scaffold. Current research focuses on prodrug strategies and formulation approaches to overcome rapid glucuronidation observed in preclinical models. The compound's unique combination of synthetic accessibility and biological relevance positions it as a valuable tool for medicinal chemistry innovation in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)